Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | EYA2 | O00167 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316378 | 0.91 | TDP1 (0.61) | TDP1EYA2APPACETSHR | |
| SCHEMBL6254463 | 0.90 | TDP1 (0.68) | TDP1EYA2APPACETSHR | |
| SCHEMBL8988039 | 0.90 | TDP1 (0.68) | TDP1EYA2APPACETSHR | |
| SCHEMBL170505 | 0.90 | TSHR (0.65) | TDP1EYA2APPACETSHR | |
| SCHEMBL19018808 | 0.87 | TSHR (0.70) | TDP1EYA2APPACETSHR | |
| SCHEMBL16317687 | 0.87 | TSHR (0.70) | TDP1EYA2APPACETSHR | |
| SCHEMBL18251067 | 0.87 | TDP1 (0.65) | TDP1EYA2APPACETSHR | |
| SCHEMBL1102344 | 0.87 | TDP1 (0.70) | TDP1EYA2APPACETSHR | |
| SCHEMBL30788728 | 0.87 | TSHR (0.62) | TDP1EYA2APPACETSHR | |
| Hydrochloric Acid SCHEMBL7108936 | 0.87 | TSHR (0.62) | TDP1EYA2APPACETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| CN-112574061-B | TRPV1 agonist and preparation method and application thereof | 南京清普生物科技有限公司 | 2023-05-19 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021063373-A1 | TRPV1 AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京清普生物科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-20160120987-A1 | CHEMICAL STRUCTURES FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-05-05 | — | — | US | disclosed |
| US-7973162-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| CN-1642929-B | Kappa-opioid receptor agonists containing 2-phenylbenzothiazoline derivatives | SANTEN PHARMACEUTICAL CO LTD | 2010-05-12 | — | — | CN | disclosed |
| CN-100522954-C | Kappa-opioid receptor agonist composed of 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| CN-1911918-A | Kappa-opioid receptor agonist composed of 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5498609-A | Benzoazepinyl compounds as oxytocin and vasopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| EP-0612319-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994004525-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| US-3954845-A | Synthetic detergents of the ampholytic betaine type, process for preparing the same and compositions | MODOKEMI AKTIEBOLAG (SW) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | TDP1 2781/4885EYA2 2003/4885APP 1245/4885 |
| US-20160120987-A1 | CHEMICAL STRUCTURES FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS | FABP1, EPCAM, CD44 | TDP1 3097/4885EYA2 908/4885APP 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.